[New possibilities in the pharmacologic prevention of age-related macular degeneration]

Orvosi Hetilap
|January 16, 2008
PubMed

Insights

Treating endothelial dysfunction may prevent or slow vision loss from age-related macular degeneration (AMD). Medications like ACE-inhibitors, AR-blockers, statins, aspirin, and trimetazidine are suggested for AMD patients and those at risk.

Area of Science:

  • Ophthalmology and Cardiovascular Medicine
  • Endothelial Dysfunction Research
  • Pharmacological Interventions

Context:

  • The vascular system's physiological and pathological uniformity suggests shared therapeutic strategies.
  • Endothelial dysfunction is a key factor in cardiovascular diseases and increasingly implicated in age-related macular degeneration (AMD).
  • Current AMD etiology and therapy remain largely unknown, highlighting the need for novel treatment approaches.

Purpose:

  • To propose treating endothelial dysfunction as a therapeutic strategy for age-related macular degeneration (AMD).
  • To investigate the potential benefits of cardiovascular medications in managing AMD.
  • To identify patient groups who could benefit from preventative or therapeutic interventions targeting endothelial dysfunction in AMD.

Summary:

  • Endothelial dysfunction contributes to AMD pathogenesis.
  • ACE-inhibitors, AR-blockers, statins, and aspirin possess pleiotropic effects beneficial for endothelial health.
  • Trimetazidine may serve as an adjuvant therapy to restore retinal tissue metabolism.
  • These medications can help rebalance vasodilators/vasoconstrictors, growth factors, inflammatory mediators, and prothrombotic/fibrinolytic factors.

Impact:

  • Suggests a novel, preventative, and therapeutic approach for AMD by targeting endothelial dysfunction.
  • Recommends specific pharmacological treatments (ACE-inhibitors, AR-blockers, statins, aspirin, trimetazidine) for different AMD patient groups.
  • Emphasizes the importance of managing cardiovascular risk factors to mitigate AMD progression.

Related Concept Videos

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption01:22

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption

As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Diabetic Retinopathy01:27

Diabetic Retinopathy

DefinitionDiabetic retinopathy is a microvascular complication of diabetes affecting the retinal blood vessels.Risk FactorsDiabetic retinopathy is present in almost all individuals with type 1 diabetes and more than 60% of those with type 2 diabetes after two decades of disease.The risk increases with poor glycemic control, hypertension, dyslipidemia, smoking, pregnancy, and puberty.Although cataracts and glaucoma are also more frequent in people with diabetes, retinopathy remains the leading...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...